Free tool
FAERS Monitor: Novolin 70/30
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 019991 or its brand name (Novolin 70/30, Insulin Recombinant Human, Insulin Susp Isophane Recombinant Human). Reports on generic versions are filed under their own applications.
Reports
5,946
Serious
3,872
65% of reports
Hospitalization
2,065
Death reported
612
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased902
- nausea354
- blood glucose decreased349
- drug ineffective291
- dyspnoea287
- dizziness255
- fatigue231
- diarrhoea224
- death222
- asthenia208
- renal failure202
- weight decreased202
- vomiting197
- headache196
- pain191
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 113 |
| 2005 | 155 |
| 2006 | 247 |
| 2007 | 183 |
| 2008 | 136 |
| 2009 | 212 |
| 2010 | 247 |
| 2011 | 234 |
| 2012 | 253 |
| 2013 | 217 |
| 2014 | 282 |
| 2015 | 684 |
| 2016 | 430 |
| 2017 | 445 |
| 2018 | 513 |
| 2019 | 449 |
| 2020 | 242 |
| 2021 | 223 |
| 2022 | 163 |
| 2023 | 98 |
| 2024 | 197 |
| 2025 | 155 |
| 2026 | 68 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,213 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood glucose decreasedSignal | 349 | 25.9 | 23.4 | 8,284 |
| blood glucose increasedSignal | 902 | 17.0 | 16.0 | 13,634 |
| renal failureSignal | 202 | 5.4 | 4.7 | 721 |
| weight decreasedSignal | 202 | 2.6 | 2.2 | 193 |
| asthenia | 208 | 2.0 | 1.7 | 98 |
| dizziness | 255 | 1.8 | 1.6 | 94 |
| dyspnoea | 287 | 1.8 | 1.6 | 103 |
| nausea | 354 | 1.6 | 1.4 | 78 |
| vomiting | 197 | 1.5 | 1.3 | 31 |
| diarrhoea | 224 | 1.2 | 1.1 | 10 |
| headache | 196 | 1.1 | 1.0 | 2 |
| pain | 191 | 1.1 | 1.0 | 2 |
| fatigue | 231 | 1.0 | 0.9 | 1 |
| death | 222 | 0.9 | 0.8 | 2 |
| drug ineffective | 291 | 0.8 | 0.7 | 19 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.